• 0 Posts
  • 34 Comments
Joined 1 year ago
cake
Cake day: March 10th, 2025

help-circle



  • Libertarians in the US want small government on three axes: they want to eliminate programs (e.g. welfare, retirement or universal healthcare), public utilities (e.g. electricity, highways), and regulation (e.g. antitrust, banking laws.) in economic terms, it’s very right-wing, since it’s pure unadulterated capitalism. usually they want government to “stay out of the bedroom and the boardroom” though, so they’re often progressive on civil liberties. unfortunately, many self-styled “libertarians” are socially conservative, or care only about their freedoms.

    Left Libertarians see both the State and Corporations as oppressive power structures, and want to reign both in. think Anarchists, but not as radical. most favor decentralized, collective government with lots of direct democracy. New Hampshire is the most right-libertarian state, while Vermont is the most left-libertarian.

    the Libertarian Party in the US is ridiculously disorganized because organizing Libertarians is like herding cats. afaik there aren’t really unified Libertarian parties anywhere in the world, though maybe e.g. the Pirate Party would be close?













  • I’m a big fan and longtime reader of Derek Lowe. He called attention to suppression of grant funding for hypotheses that challenged the amyloid hypothesis, and the shockingly partisan and dogmatic behavior of journal referees and NIH advisors in the field. I’ve been following his coverage ever since he started reporting disappointing readouts from clinical trials on the anti-amyloid mABs.

    His concern that this class of therapy is “pathological science” (think cold fusion, or EmDrive, or string theory - not outright quackery, but hypotheses that are endlessly tweaked to justify the latest failures) are valid.

    However, the newest mABs really do seem to have a small but statistically significant effect on slowing disease progression. Enough to justify the risks of brain swelling? Or the cost? Probably not. But I think Derek has perhaps swung too far in the opposite direction. It’s too early to call time on this therapeutic target. If it’s marginally but truly effective, we should try to figure out why, and keep tweaking the drugs to see if they can be improved.

    Donepezil was a dead end, but it’s too early to say if Aduhelm is too.